Emerging Infectious Diseases (Jun 2025)

Cadaveric Human Growth Hormone–Associated Creutzfeldt-Jakob Disease with Long Latency Period, United States

  • Anatevka S. Ribeiro,
  • Andrew B. Wolf,
  • Ellen W. Leschek,
  • Lawrence B. Schonberger,
  • Joseph Y. Abrams,
  • Ryan A. Maddox,
  • Brian S. Appleby,
  • Katie Glisic,
  • Aaron Carlson,
  • Elizabeth Matthews

DOI
https://doi.org/10.3201/eid3106.241519
Journal volume & issue
Vol. 31, no. 6
pp. 1189 – 1192

Abstract

Read online

We report a case of iatrogenic Creutzfeldt-Jakob disease (iCJD) after a 48.3-year incubation period in a patient treated with cadaveric human growth hormone. iCJD was pathologically confirmed; genetic analysis was negative for pathogenic mutations. Clinicians should consider iCJD in patients with progressive neurologic signs who had received cadaveric human growth hormone treatment.

Keywords